Scarica l'app Stockscreener
3.99
5.23%
-0.22
Precedente Chiudi:
$4.21
Aprire:
$4.3
Volume 24 ore:
67,812
Relative Volume:
2.48
Capitalizzazione di mercato:
$7.67M
Reddito:
$6.50M
Utile/perdita netta:
$-29.58M
Rapporto P/E:
-0.2442
EPS:
-16.3362
Flusso di cassa netto:
$-34.58M
1 W Prestazione:
-16.35%
1M Prestazione:
-8.49%
6M Prestazione:
-22.60%
1 anno Prestazione:
-29.51%
Intervallo 1D:
$3.99
$4.59
Intervallo di 1 settimana:
$3.99
$4.92
Portata 52W:
$3.91
$7.1999
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Nome
Bolt Biotherapeutics Inc
Settore
Industria
Telefono
650-665-9295
Indirizzo
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
3.99 | 7.67M | 6.50M | -29.58M | -34.58M | -16.34 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | Iniziato | Guggenheim | Buy |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
Mostra tutto
Bolt Biotherapeutics Inc Borsa (BOLT) Ultime notizie
Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bolt Biotherapeutics Inc (BOLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bolt Biotherapeutics Inc (BOLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bolt Biotherapeutics Inc (BOLT) Institutional Confidence - TradingKey
Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bolt Biotherapeutics Inc (BOLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Large EPS Miss Reflects Continued R&D InvestmentEPS Growth Rate - newsline.com
Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike price - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike - Stock Titan
Bolt Biotherapeutics (BOLT) Declines Over 4%, Nears Critical Support LevelWeekly Profile - newsline.com
Bolt Biotherapeutics (BOLT) Slides 4% Amid Biotech Sector Turbulence – Key Levels to WatchComposite Profile - newsline.com
BOLT Q1 2026 Earnings: Deep EPS Miss Highlights Operational ChallengesPost-Earnings Drift - newsline.com
Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw - Moomoo
BOLT Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics (BOLT) Gains 2.32%: Biotech Stock Approaches Key Resistance LevelIchimoku Kumo Twist - The Legal Advocate
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating - Investing.com
Bolt Biotherapeutics (BOLT) Edges Higher Amid Tight Trading Range – Support and Resistance Levels in FocusWyckoff Distribution - The Legal Advocate
Bolt Biotherapeutics Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue StageDiluted EPS Report - newsline.com
Bolt Biotherapeutics (BOLT) Slips 1.2% as Shares Test Key Support at $4.65Breadth Thrust - The Legal Advocate
Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates - MSN
Bolt Biotherapeutics, Inc.Common Stock (NQ: BOLT - The Chronicle-Journal
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics: Cash on Hand Is Expected to Fund Ops Into 2027 - Moomoo
Press Release: Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results - TradingView
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - marketscreener.com
Bolt Biotherapeutics 1Q 2026: Revenue $26K, Net loss $7.24M, EPS $(4.31) — 10-Q Summary - TradingView
Bolt Biotherapeutics (NASDAQ: BOLT) narrows Q1 loss, cuts expenses - Stock Titan
Cancer drug trial data due in 3Q 2026 as Bolt logs $7.6M operating loss - Stock Titan
BOLT (Bolt Bio) beats earnings estimates as quarterly loss narrows 38 percent, but stock flat.Asset Sale - newser.com
Bolt Biotherapeutics Inc expected to post a loss of $2.85 a shareEarnings Preview - TradingView
BOLT Q1'26 Earnings: EPS estimate is (2.85) USD - TradingView
Bolt Biotherapeutics (BOLT) 2026 proxy details director votes and auditor - Stock Titan
[ARS] Bolt Biotherapeutics, Inc. SEC Filing - Stock Titan
Is Bolt Bio (BOLT) stock moving unpredictably (Trend Strengthens) 2026-04-20Community Pattern Alerts - Cổng thông tin điện tử Tỉnh Sơn La
Operating cash flow per share of Bolt Biotherapeutics, Inc. – MUN:6LP0 - TradingView
Aug Movers: Is Bolt Biotherapeutics Inc still a buy after recent gainsMarket Activity Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Treasury Yields: Will Bolt Biotherapeutics Inc announce a stock splitWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
What is the price target for Bolt Bio (BOLT) Stock | Price at $4.75, Up 5.21%VWAP Deviation - newsline.com
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is momentum building in Bolt Bio (BOLT) Stock | Price at $4.81, Up 0.63%CTA Positioning - newsline.com
Performance Recap: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Buyback Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Bolt Biotherapeutics Inc Azioni (BOLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):